Participants 56 88 4
extensive small-cell lung cancer
Participants 287 378 3
previously untreated patients with extensive-stage small-cell carcinoma of the lung (SCLC).
Participants 400 546 6
Patients with extensive SCLC with a Karnofsky performance score (KPS) > or = 50 and adequate renal function and bone marrow reserve were eligible.
Participants 547 638 4
Patients with CNS metastases were eligible and received concurrent whole-brain radiotherapy
Participants 946 1033 5
From May 1989 through March 1993, 171 patients were randomized (84 to VP and 87 to VIP)
Participants 1768 1833 3
overall survival over VP therapy in patients with extensive SCLC.
